Remarkably, both genetic and pharmacological inhibition of ERAP1 suppresses Hh-dependent tumor growth in vitro and in vivo, suggesting an innovative therapeutic approach in the treatment of Hh-dependent tumors. This evidence concerns the gene ERAP1 and neoplasm.